Developer docs
API playgroundTry for free, no card

Search company profiles

FutureLife Group

Full company profile

uuid00wp7t7

Namestring
FutureLife Group
Legal namestring
FutureLife a.s.
Company typeenum
Private
Founded yearint
1991
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLas Vegas, United States
HQ citystring
Las Vegas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fertility treatments, IVF services, reproductive medicine, genetic testing, fertility preservation
Industry2 codes
PRIMARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
NAICS code1 code
  • Family Planning Centers621410
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Medical Laboratories8071
Product category
Reproductive Medicine and Fertility Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1IVF Treatment Cycles
TypeTransaction Fee
Description

Core revenue from fertility treatments including IVF cycles, IUI, donor programs, and fertility preservation. The company performs over 77,000 IVF cycles annually across its network.

futurelifegroup.com
2Genetic Testing Services
TypeTransaction Fee
Description

Revenue from genetic laboratory services including PGT, carrier tests, and diagnostic tests through GNTlabs by GENNET.

futurelifegroup.com
3Pharmacy (Serpha)
TypeTransaction Fee
Description

Online pharmacy specializing in fertility medication, operating across Netherlands and other markets.

futurelifegroup.com
4Hospital and Surgical Services
TypeTransaction Fee
Description

Two hospitals in Czech Republic plus gynecological and surgical treatments at clinic network.

futurelifegroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 7 records shown
1GNTlabs by GENNET
Description

One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, PGT, and bioinformatics

futurelifegroup.com
+6 more records
Core offering1 text field

FutureLife Group operates a pan-European network of fertility, IVF, and genetics clinics delivering assisted reproduction services such as IVF, IUI, donor programmes, and fertility preservation. The group runs 62 clinics across 16 countries supported by an in-house genetic laboratory (GNTlabs by GENNET) and an online fertility pharmacy (Serpha). It has performed more than 77,000 IVF cycles annually and integrated a CE-marked AI platform (Embryo Predict, Success Predictor, Egg Retrieval Report) network-wide for clinical decision support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 188,795 babies delivered since 1991 (one every 36 minutes)
+4 more records
Product overview1 text field

FutureLife Group is a pan-European fertility and reproductive medicine provider operating a multi-brand, multi-clinic platform. The core offering includes fertility treatments (IUI, IVF, donor programmes, fertility preservation) supported by the FutureLife Gamete Bank and GNTlabs genetic laboratory. The company has expanded through acquisitions of leading regional fertility brands including CRGH, Herts & Essex, BCRM, Institut Marquès, Nij Group, Nova Vita/Ovumia, BabyScan, and clinics in Romania (Gynera, Gynatal, Atentica, CytoGenomic), as well as the Bahceci Group in Turkey. Recent AI integration includes deployment of Alife Health's Embryo Predict, Success Predictor, and Egg Retrieval Report tools across the clinic network.

Product and service11 records
1In Vitro Fertilization (IVF)
CategoryCore fertility treatment
Description

A highly effective fertility treatment where fertility hormones stimulate the ovaries to produce eggs, which are collected and combined with sperm in a laboratory to create embryos for transfer. Offered to individuals and couples experiencing infertility across FutureLife's network of 62 clinics in 16 European countries.

2Intrauterine Insemination (IUI)
CategoryCore fertility treatment
Description

A fertility treatment involving placement of sperm directly inside the womb around the time of ovulation, performed in natural or medicated cycles. Less invasive than IVF and offered to patients across the FutureLife clinic network.

3Donor Programme
CategoryCore fertility treatment
Description

Treatment pathway using donated eggs or sperm to help individuals and couples create families, supported by FutureLife Gamete Bank as Europe's leading donor egg bank.

4Fertility Preservation (Egg Freezing)
CategoryCore fertility treatment
Description

Oocyte cryopreservation allowing women to preserve fertility by freezing and storing eggs for future use, including for medical (e.g., before cancer treatment) or social reasons. Offered across FutureLife's clinic network.

5FutureLife Gamete Bank
CategoryDonor and gamete services
Description

Europe's leading donor egg bank providing best-in-class assisted reproductive technology care through thorough screening, skilled doctors, and a caring approach to maximize chances of success for patients across Europe.

6GNTlabs by GENNET
CategoryGenetic laboratory services
Description

One of Europe's most advanced genetic laboratories, operated as a wholly owned subsidiary of FutureLife, specializing in molecular genetics, cytogenetics, preimplantation genetic testing (PGT), bioinformatics, embryology, and immunology. Offers disease risk screenings, carrier tests, and diagnostic tests for genetic disorders.

7Serpha Online Pharmacy
CategoryPharmacy services
Description

Online pharmacy operated as a wholly owned subsidiary of FutureLife (via Nij Group), specializing in fertility medication and serving patients across the Netherlands and other markets.

8Embryo Predict
CategoryAI clinical decision support
Description

CE-marked AI tool for blastocyst evaluation and embryo assessment for transfer decisions. Uses deep learning to generate AI scores for each embryo alongside personalized patient reports. Part of Alife Health AI platform deployed across FutureLife's clinic network.

9Success Predictor
CategoryAI clinical decision support
Description

Non-medical device tool providing outcome projections before fertility treatment, part of the Alife Health AI platform for patient decision support throughout the IVF journey.

10Egg Retrieval Report
CategoryAI clinical decision support
Description

Tool offering patients visibility into their evolving chances of success following egg retrieval, part of the Alife Health AI platform providing patient support across the IVF journey.

11Linea Vita Genetic Test
CategoryGenetic testing services
Description

First carrier screening test developed in Romania, analyzing 150 genes responsible for 217 genetic disorders, offered through CytoGenomic Medical Laboratory in partnership with FutureLife.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-05
Description

Network-wide partnership to deploy comprehensive AI platform for fertility care across all 60 clinics in 16 countries. Includes CE-marked Embryo Predict™ for blastocyst evaluation, Success Predictor™, and Egg Retrieval Report tools. FutureLife becomes the first large-scale European fertility network to adopt a multi-tool AI platform following successful multi-clinic pilot.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-05
Description

Deploys AI platform across 60+ clinics including Embryo Predict™ (CE-marked), Success Predictor™, and Egg Retrieval Report tools for comprehensive AI-assisted fertility care.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

EIH partnered with FutureLife to introduce Institut Marquès to UAE capital, paving way for regional expansion with Abu Dhabi center opening during 2026.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Strategic partnership to bring Institut Marquès to Abu Dhabi, UAE. New center will offer IVF, fertility treatments, gynecology, holistic therapies, and wellness programs. EIH is UAE's leading progressive investment holding.

5CytoGenomic Medical Laboratory
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Partnership with Romania's leading genetic laboratory providing innovative genetic analysis and tests. CytoGenomic collaborates with 45+ clinics and hospitals, providing 15,000+ genetic analyses annually including Linea Vita carrier screening test.

futurelifegroup.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Australia-headquartered global IVF provider with clinics across Australia, Ireland, the UK, and Singapore. Comparable as a multi-brand fertility clinic network pursuing international expansion via M&A, though it is more concentrated in the Southern Hemisphere.

TypeRegional player
Description

One of the largest US fertility clinic networks with affiliated centers across North America. Comparable as a multi-clinic fertility provider serving a similar patient base, but operating almost entirely in the US rather than Europe.

TypeOthers
Description

Global supplier of media, consumables, and GeneSYS preimplantation genetic testing to IVF clinics. Comparable as an ecosystem enabler providing technology and lab tools that complement FutureLife's clinical operations.

TypeOthers
Description

US-based AI platform partner for IVF clinics (Embryo Predict, Success Predictor, Egg Retrieval Report). Comparable as a strategic technology partner whose product roadmap directly shapes FutureLife's clinical AI differentiation.

TypeDirect peer
Description

Global fertility company operating clinics in Australia and the UK plus a medical devices arm (Genea Biomedx). Comparable as a vertically integrated fertility network with proprietary lab technology serving a similar patient base.

TypeDirect peer
Description

UK-based fertility clinic network offering IVF, IUI, donor programs, and genetic testing. Directly competes with FutureLife's UK brands (CRGH, BCRM, Herts & Essex) for NHS-funded and private-pay patients.

TypeBroad incumbent
Description

Large diversified fertility and women's health business within CooperCompanies, providing ART media, devices, and genetic testing globally. Comparable as a broad incumbent supplying — and increasingly integrating into — IVF clinical workflows.

TypeDirect peer
Description

World's largest assisted reproduction group, operating a network of fertility clinics across Europe, the Americas, and the Middle East. Directly comparable as a multi-country IVF clinic consolidator with full reproductive medicine, genetic, and donor services — FutureLife's clearest pan-European competitor.

9Monash IVF Group
TypeRegional player
Description

Australia- and Southeast Asia-focused fertility clinic network with ultrasound and genetics services. Comparable as a multi-clinic reproductive medicine platform, but primarily Asia-Pacific rather than European in footprint.

TypeDirect peer
Description

European fertility clinic group operating across the UK, Poland, the Netherlands, Denmark, and Germany. Direct competitor in the same European fertility-clinic consolidation space, focused on NHS and private-pay cycles.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries15 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FutureLife Group

Reproductive Medicine and Fertility Servicesfuturelifegroup.com

FutureLife Group firmographics

Firmographics
Name
FutureLife Group
Legal name
FutureLife a.s.
Website
https://futurelifegroup.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

FutureLife Group industry classification

Industry
Product category
Reproductive Medicine and Fertility Services
NAICS
Family Planning Centers (621410)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals

Keywords

  • Fertility treatments
  • IVF services
  • Reproductive medicine
  • Genetic testing
  • Fertility preservation

Where FutureLife Group is headquartered

Location

Headquarters

HQ city
Las Vegas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

FutureLife Group business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. IVF Treatment Cycles: Core revenue from fertility treatments including IVF cycles, IUI, donor programs, and fertility preservation. The company performs over 77,000 IVF cycles annually across its network.
  2. Genetic Testing Services: Revenue from genetic laboratory services including PGT, carrier tests, and diagnostic tests through GNTlabs by GENNET.
  3. Pharmacy (Serpha): Online pharmacy specializing in fertility medication, operating across Netherlands and other markets.
  4. Hospital and Surgical Services: Two hospitals in Czech Republic plus gynecological and surgical treatments at clinic network.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

FutureLife Group product offering

Product offering

Core offering

FutureLife Group operates a pan-European network of fertility, IVF, and genetics clinics delivering assisted reproduction services such as IVF, IUI, donor programmes, and fertility preservation. The group runs 62 clinics across 16 countries supported by an in-house genetic laboratory (GNTlabs by GENNET) and an online fertility pharmacy (Serpha). It has performed more than 77,000 IVF cycles annually and integrated a CE-marked AI platform (Embryo Predict, Success Predictor, Egg Retrieval Report) network-wide for clinical decision support.

Product overview

FutureLife Group is a pan-European fertility and reproductive medicine provider operating a multi-brand, multi-clinic platform. The core offering includes fertility treatments (IUI, IVF, donor programmes, fertility preservation) supported by the FutureLife Gamete Bank and GNTlabs genetic laboratory. The company has expanded through acquisitions of leading regional fertility brands including CRGH, Herts & Essex, BCRM, Institut Marquès, Nij Group, Nova Vita/Ovumia, BabyScan, and clinics in Romania (Gynera, Gynatal, Atentica, CytoGenomic), as well as the Bahceci Group in Turkey. Recent AI integration includes deployment of Alife Health's Embryo Predict, Success Predictor, and Egg Retrieval Report tools across the clinic network.

Differentiator

Problem solved

Functional benefit

Brands

  • GNTlabs by GENNET: One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, PGT, and bioinformatics
  • FutureLife Gamete Bank
  • Serpha
  • CRGH
  • Reprofit
  • GENNET
  • City Fertility

Products and services

  • In Vitro Fertilization (IVF) A highly effective fertility treatment where fertility hormones stimulate the ovaries to produce eggs, which are collected and combined with sperm in a laboratory to create embryos for transfer. Offered to individuals and couples experiencing infertility across FutureLife's network of 62 clinics in 16 European countries.
  • Intrauterine Insemination (IUI) A fertility treatment involving placement of sperm directly inside the womb around the time of ovulation, performed in natural or medicated cycles. Less invasive than IVF and offered to patients across the FutureLife clinic network.
  • Donor Programme Treatment pathway using donated eggs or sperm to help individuals and couples create families, supported by FutureLife Gamete Bank as Europe's leading donor egg bank.
  • Fertility Preservation (Egg Freezing) Oocyte cryopreservation allowing women to preserve fertility by freezing and storing eggs for future use, including for medical (e.g., before cancer treatment) or social reasons. Offered across FutureLife's clinic network.
  • FutureLife Gamete Bank Europe's leading donor egg bank providing best-in-class assisted reproductive technology care through thorough screening, skilled doctors, and a caring approach to maximize chances of success for patients across Europe.
  • GNTlabs by GENNET One of Europe's most advanced genetic laboratories, operated as a wholly owned subsidiary of FutureLife, specializing in molecular genetics, cytogenetics, preimplantation genetic testing (PGT), bioinformatics, embryology, and immunology. Offers disease risk screenings, carrier tests, and diagnostic tests for genetic disorders.
  • Serpha Online Pharmacy Online pharmacy operated as a wholly owned subsidiary of FutureLife (via Nij Group), specializing in fertility medication and serving patients across the Netherlands and other markets.
  • Embryo Predict CE-marked AI tool for blastocyst evaluation and embryo assessment for transfer decisions. Uses deep learning to generate AI scores for each embryo alongside personalized patient reports. Part of Alife Health AI platform deployed across FutureLife's clinic network.
  • Success Predictor Non-medical device tool providing outcome projections before fertility treatment, part of the Alife Health AI platform for patient decision support throughout the IVF journey.
  • Egg Retrieval Report Tool offering patients visibility into their evolving chances of success following egg retrieval, part of the Alife Health AI platform providing patient support across the IVF journey.
  • Linea Vita Genetic Test First carrier screening test developed in Romania, analyzing 150 genes responsible for 217 genetic disorders, offered through CytoGenomic Medical Laboratory in partnership with FutureLife.

Quantifiable outcome

  • Over 188,795 babies delivered since 1991 (one every 36 minutes)
  • +4 more outcomes

Companies that use FutureLife Group

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

FutureLife Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

FutureLife Group partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • Alife HealthcoreTechnology or Integration · 5 May 2026Network-wide partnership to deploy comprehensive AI platform for fertility care across all 60 clinics in 16 countries. Includes CE-marked Embryo Predict™ for blastocyst evaluation, Success Predictor™, and Egg Retrieval Report tools. FutureLife becomes the first large-scale European fertility network to adopt a multi-tool AI platform following successful multi-clinic pilot.
  • Alife HealthcoreTechnology or Integration · 5 May 2026Deploys AI platform across 60+ clinics including Embryo Predict™ (CE-marked), Success Predictor™, and Egg Retrieval Report tools for comprehensive AI-assisted fertility care.
  • Ethmar International Holding (EIH)majorStrategic or Co-development Partner · 1 January 2026EIH partnered with FutureLife to introduce Institut Marquès to UAE capital, paving way for regional expansion with Abu Dhabi center opening during 2026.
  • Ethmar International Holding (EIH)majorStrategic or Co-development Partner · 22 December 2025Strategic partnership to bring Institut Marquès to Abu Dhabi, UAE. New center will offer IVF, fertility treatments, gynecology, holistic therapies, and wellness programs. EIH is UAE's leading progressive investment holding.
  • CytoGenomic Medical LaboratorycoreStrategic or Co-development Partner · 3 November 2022Partnership with Romania's leading genetic laboratory providing innovative genetic analysis and tests. CytoGenomic collaborates with 45+ clinics and hospitals, providing 15,000+ genetic analyses annually including Linea Vita carrier screening test.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

FutureLife Group competitors and assessment

Company assessment

Broad incumbents

  • Virtus Health: Australia-headquartered global IVF provider with clinics across Australia, Ireland, the UK, and Singapore. Comparable as a multi-brand fertility clinic network pursuing international expansion via M&A, though it is more concentrated in the Southern Hemisphere.
  • CooperCompanies (CooperSurgical): Large diversified fertility and women's health business within CooperCompanies, providing ART media, devices, and genetic testing globally. Comparable as a broad incumbent supplying — and increasingly integrating into — IVF clinical workflows.

Regional players

  • Boston IVF: One of the largest US fertility clinic networks with affiliated centers across North America. Comparable as a multi-clinic fertility provider serving a similar patient base, but operating almost entirely in the US rather than Europe.
  • Monash IVF Group: Australia- and Southeast Asia-focused fertility clinic network with ultrasound and genetics services. Comparable as a multi-clinic reproductive medicine platform, but primarily Asia-Pacific rather than European in footprint.

Others

  • Vitrolife: Global supplier of media, consumables, and GeneSYS preimplantation genetic testing to IVF clinics. Comparable as an ecosystem enabler providing technology and lab tools that complement FutureLife's clinical operations.
  • Alife Health: US-based AI platform partner for IVF clinics (Embryo Predict, Success Predictor, Egg Retrieval Report). Comparable as a strategic technology partner whose product roadmap directly shapes FutureLife's clinical AI differentiation.

Direct peers

  • Genea: Global fertility company operating clinics in Australia and the UK plus a medical devices arm (Genea Biomedx). Comparable as a vertically integrated fertility network with proprietary lab technology serving a similar patient base.
  • CARE Fertility: UK-based fertility clinic network offering IVF, IUI, donor programs, and genetic testing. Directly competes with FutureLife's UK brands (CRGH, BCRM, Herts & Essex) for NHS-funded and private-pay patients.
  • IVI-RMA Global: World's largest assisted reproduction group, operating a network of fertility clinics across Europe, the Americas, and the Middle East. Directly comparable as a multi-country IVF clinic consolidator with full reproductive medicine, genetic, and donor services — FutureLife's clearest pan-European competitor.
  • TFP Fertility: European fertility clinic group operating across the UK, Poland, the Netherlands, Denmark, and Germany. Direct competitor in the same European fertility-clinic consolidation space, focused on NHS and private-pay cycles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

FutureLife Group social profiles

Digital presence

FutureLife Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FutureLife Group leadership team

Management profile

Number of profiles

Profiles4 records

FutureLife Group subsidiaries and ownership

Company hierarchy

Subsidiaries15 records

FutureLife Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FutureLife Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FutureLife Group

What does FutureLife Group do?

FutureLife Group operates a pan-European network of fertility, IVF, and genetics clinics delivering assisted reproduction services such as IVF, IUI, donor programmes, and fertility preservation. The group runs 62 clinics across 16 countries supported by an in-house genetic laboratory (GNTlabs by GENNET) and an online fertility pharmacy (Serpha). It has performed more than 77,000 IVF cycles annually and integrated a CE-marked AI platform (Embryo Predict, Success Predictor, Egg Retrieval Report) network-wide for clinical decision support.

Is FutureLife Group a public or private company?

FutureLife Group is a private company. It is classified as private equity controlled and is currently operating.

When was FutureLife Group founded?

FutureLife Group was founded in 1991. It employs 1 to 10 people.

Where is FutureLife Group based?

FutureLife Group is headquartered in Las Vegas, United States, in the North America region.

How does FutureLife Group make money?

Four revenue lines are on record. IVF Treatment Cycles are the primary driver. The others are genetic Testing Services, pharmacy (Serpha) and hospital and Surgical Services.

Who are FutureLife Group's main competitors?

Broad incumbents on record are Virtus Health and CooperCompanies (CooperSurgical). Regional players are Boston IVF and Monash IVF Group. Others are Vitrolife and Alife Health. Direct peers are Genea, CARE Fertility, IVI-RMA Global and TFP Fertility.

Does FutureLife Group have an API?

No public API is recorded for FutureLife Group.

What industry is FutureLife Group in?

FutureLife Group's product category is Reproductive Medicine and Fertility Services. Its primary akta.pro industry code is HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers, with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 621410 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaHerts & Essex Fertility Centre sold to FutureLife GroupHerts & Essex Fertility Centre in Cheshunt, Hertfordshire, has been sold to FutureLife Group, a major European fertility operator running 60 clinics across 16 countries. The acquisition marks FutureLife's third UK location, joining the Bristol Centre for Reproductive Medicine and the Centre for Reproductive and Genetic Health in central London. The founder stated the deal will allow the centre to build on its strong foundations while preserving its values and quality of care.HertsandessexfertilityFutureLife Group Acquires Herts & Essex Fertility CentreFutureLife Group, a pan-European fertility and IVF services provider backed by CVC Capital Partners and Hartenberg Holding, announced an agreement to acquire Herts & Essex Fertility Centre in the UK. The acquisition adds the southeast England fertility centre to FutureLife's portfolio, which already includes BCRM and CRGH, strengthening its presence across the south of the UK. Herts & Essex has over 35 years of experience, has supported over 8,000 families, and delivers more than 1,000 cycles annually.EclipsecfFertility M&A LandscapeThe UK fertility market is experiencing rapid growth, driven by technological innovations and a shift toward private clinics as NHS access declines. This expansion has triggered significant M&A activity, with companies such as FutureLife, Care Fertility, and the London Women’s Clinic acquiring various reproductive health centers to consolidate their market presence.BristolworldFertility services group acquires Bristol Centre for Reproductive MedicineFutureLife, a European fertility services group, acquired the Bristol Centre for Reproductive Medicine (BCRM). BCRM, serving over 1,000 patients annually, will expand FutureLife's UK presence. The acquisition aims to harmonize best practices while preserving each clinic's clinical autonomy.Empresas de Capital Riesgo en EspaFutureLife, backed by Hartenberg Holding and CVC Capital Partners, has announced the acquisition of Institut Marquès, a leading IVF company located in BarcelonaFutureLife has acquired Institut Marquès, a leading IVF company based in Barcelona, supported by its backers Hartenberg Holding and CVC Capital Partners. Institut Marquès, known for its patient-centric approach, performs over 3,000 egg collections annually and operates multiple clinics in Spain and Italy. This partnership aims to enhance the scale of innovative projects in assisted reproduction across Europe.FuturelifegroupCRGH + FutureLifeFutureLife, a Pan-European IVF provider backed by CVC Capital Partners and Hartenberg Holding, has acquired the Centre for Reproductive and Genetic Health (CRGH), a leading private fertility clinic in Central London. This transaction strengthens FutureLife's presence in the UK market by integrating CRGH with its existing City Fertility clinic to share best practices and expand operations.